

**Diagnostic Assessment Report commissioned by the NIHR HTA
Programme on behalf of the National Institute for Health and Care
Excellence – Table of errata**

Title of project:

Clinical and cost-effectiveness of use of therapeutic monitoring of TNF α inhibitors (LISA-TRACKER ELISA kits, TNF α -Blocker ELISA kits, and Promonitor ELISA kits) versus standard care in people with Crohn's disease: systematic reviews and economic modelling

Name of External Assessment Group (EAG) and project lead:

Produced by: Warwick Evidence
Lead author: Karoline Freeman
Co-authors: Martin Connock
Peter Auguste
Sian Taylor-Phillips
Hema Mistry
Deepson Shyangdan
Rachel Court
Ramesh Arasaradnam
Paul Sutcliffe
Aileen Clarke

Correspondence to: Dr Paul Sutcliffe
Associate Professor
Deputy Director for Warwick Evidence
Populations, Evidence and Technologies
Division of Health Sciences
Warwick Medical School
University of Warwick
Coventry CV4 7AL

Tel: 02476 150189
Fax: 02476 528375
Email: p.a.sutcliffe@warwick.ac.uk

Corrections to the main document are underlined.

DAR section	Page number	DAR text	Corrected text
4.3.1.2	147	'administration costs were also included for adalimumab'	'administration costs were also included for <u>infliximab</u> '
4.3.4.2.2	173	'for people switching to adalimumab, we derived a cost of £1408.28 (2x £704.28, assuming 40mg of adalimumab is required every two weeks) per four-week cycle'	'for people switching to adalimumab, we derived a cost of <u>£704.28</u> (2 x <u>£352.14</u> ; assuming 40mg of adalimumab is required every two weeks) per four-week cycle
4.3.4.2.2 Table 35	173	Base case value maintenance adalimumab: 704.28'	Base case value maintenance adalimumab: <u>352.14</u>
8.18 Table 56	376	unit cost for adalimumab 40mg every other week: 704.28	unit cost for adalimumab 40mg every other week: <u>352.14</u>

Addendum Table 5 Model results using time to event versus exponential transition probabilities

Time to event						Exponential					
Testing strategy	Mean cost per strategy	Difference in costs	Effectiveness (QALYs)	Incremental QALYs	Incremental cost-effectiveness ratio (£) (ICER)	Testing strategy	Mean cost per strategy	Difference in costs	Effectiveness (QALYs)	Incremental QALYs	Incremental cost-effectiveness ratio (£) (ICER)
No regain response following best supportive care (responders)						No regain response following best supportive care (responders)					
Concurrent testing	86,900	-	5.7472	-	-	No testing	150,550	-	6.5084	-	-
Reflex testing	87,700	800	5.7760	0.0288	27,800	Reflex testing	158,300	7750	6.4813	-0.02710	Dominated
No testing	137,600	49,900	6.5143	0.7383	67,600	Concurrent testing	160,800	10,250	6.4813	-0.00001	Dominated

Errata for Addendum Table 5 Model results using time to event versus exponential transition probabilities

Time to event						Exponential					
Testing strategy	Mean cost per strategy	Difference in costs	Effectiveness (QALYs)	Incremental QALYs	Incremental cost-effectiveness ratio (£) (ICER)	Testing strategy	Mean cost per strategy	Difference in costs	Effectiveness (QALYs)	Incremental QALYs	Incremental cost-effectiveness ratio (£) (ICER)
No regain response following best supportive care (responders)						No regain response following best supportive care (responders)					
Concurrent testing	86,900	-	5.7472	-	-	<u>Reflex testing</u>	<u>87,900</u>	=	<u>5.7853</u>	=	=
Reflex testing	87,700	800	5.7760	0.0288	27,800	<u>Concurrent testing</u>	<u>89,900</u>	<u>2000</u>	<u>5.7838</u>	<u>-0.0015</u>	<u>Dominated</u>
No testing	137,600	49,900	6.5143	0.7383	67,600	<u>No testing</u>	<u>150,500</u>	<u>62,600</u>	<u>6.5084</u>	<u>0.7231</u>	<u>86,600</u>